Clinical Trial Update: Iadademstat in Combination With Paclitaxel in Relapsed/Refractory SCLC and Extrapulmonary High Grade NET [Phase 2]

View source ↗

Summary

A Phase 2 trial of iadademstat in combination with paclitaxel for relapsed/refractory small-cell lung cancer and extrapulmonary high-grade neuroendocrine tumors…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Carcinoma
• Small Cell Lung Cancer

Drugs mentioned

• Iadademstat (iadademstat)
• PACLITAXEL (PACLITAXEL)

Snippet

Sponsor: Fox Chase Cancer Center | Conditions: Small-cell Lung Cancer, Neuroendocrine Carcinoma | Phase 2 | Status: TERMINATED